Impact of the COVID-19 pandemic on colorectal cancer (CRC) care: Data from 22 German cancer centers (CC) and the Institute of Pathology, Ruhr-University Bochum - the AIO (Working Group for Internal Oncology of the German Cancer Society) CancerCOVID Consortium - AIO-YMO/KRK 520/ass.

Authors

null

Celine Lugnier

Department of Hematology, Oncology and Palliative Care, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany

Celine Lugnier , Sarah Foerster , Anna-Lena Kraeft , Inke Sabine Feder , Jens Christmann , Eleni Kourti , Oliver Overheu , Sabine Sommerlatte , Waldemar Uhl , Martin Schoenlein , Vivian Rosery , Christoph Biermann , Lothar Müller , Olaf Schoffer , Jochen Schmitt , Dominik Paul Modest , Volker Heinemann , Jan Schildmann , Anke C. Reinacher-Schick , Andrea Tannapfel

Organizations

Department of Hematology, Oncology and Palliative Care, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany, Institute of Pathology, Georgius Agricola Stiftung Ruhr, Ruhr-University Bochum, Bochum, Germany, Bochum, Germany, Institut für Pathologie der Ruhr-Universität Bochum, Bochum, Germany, Department of Hematology and Oncology with Palliative Care, St. Josef Hospital, Ruhr University, Bochum, Germany, Martin Luther University Halle-Wittenberg, Halle, Germany, Ruhr-University Bochum, St. Josef Hospital, Bochum, Germany, Department of Internal Medicine II, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Hamburg, Germany, Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany, MVZ for Intern Medicine and Oncology Bocholt GmbH, Bocholt, Germany, Studienzentrum UnterEms und Onkologie UnterEms, Leer, Germany, Center for Evidence-Based Healthcare, University Hospital Carl Gustav Carus and Carl Gustav Carus Faculty of Medicine, Technical University Dresden, Dresden Germany, Dresden, Germany, Center for Evidence-Based Healthcare, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany, Department of Medicine III, University Hospital, LMU Munich, Munich, Germany, University Hospital, LMU Munich, Department of Medicine III, and Comprehensive Cancer Center Munich, Munich, Germany, Institute for History and Ethics of Medicine, Martin Luther University Halle-Wittenberg, Halle, Germany

Research Funding

Other Government Agency

Background: CRC still is one of the leading causes of cancer related death though prognosis has improved through guideline based management. The COVID-19 pandemic lead to re-allocation of resources subordinating all sections of care for CRC patients. We present data on changes of CRC care during the pandemic from 22 German AIO CC and our high volume Institute of Pathology (pathology). Methods: Data was collected retrospectively comparing the months (mo) of the first wave (fw) (4-6/2020) and second wave (sw) (11-12/2020) of the pandemic with corresponding periods (cp) in 2019 focusing on the number of precancerous (ICD-O/0+2) and malignant (ICD-O/3+6) colorectal lesions (CRL) diagnosed by our pathology, the number/stage of primary diagnoses (PD) and the number of surgeries (surg) at AIO CC. There, quality criteria of CRC care were also assessed (number of PD discussed within a multidisciplinary tumor board (tb), received social service (soc)/ psychological (psy) counseling or recruited into a clinical trial). Statistical analysis was performed using students t-test for paired data. Results: Numbers of CRL detected upon histology (row 1-3), number of cases, surg and quality criteria from AIO CC (row 4-9) are displayed in the table. We saw a dip in diagnosed CRL and number of surg (p=0.007) only during fw, whereas PD dipped significantly in both waves. A significant reduction in diagnosis of stage III CRC was detected for 2019 vs. 2020 (p=0.001), not for other stages. Quality criteria showed a significant reduction in clinical trial inclusion, a small dip in soc/psy counseling and persistently high tb presentation. Conclusions: We detected a significant decrease of premalignant lesions and primary cancers during the first year of the pandemic which may impact cancer mortality in the future. Certified German CC provided CRC care with significant reduction in clinical trial inclusion only, suggesting high stability of established certified cancer care infrastructure.

Detailed data from pathology (1-3) and AIO CC (4-9).

2019 total
2020 total
fw/cp

2019
fw

2020
fw

p=
sw/cp

2019
sw

2020
w

p=
2019/20

p=
Total (pathology)
30794
29901
2531
2122
2462
2390
ICD-O/0+2
27848
27046
2294
1927
2250
2161
ICD-O/3+6
2848
2750
233
191
206
224
PD (AIO CC)
2322
1995
8.5
6.8
0.004
8.4
5.7
0.005
<0.001
surg
1604
1505
7.4
5.5
0.007
7
5.6
0.23
0.003
trial
313
160
2.9
1.9
0.06
2.6
2
0.3
<0.001
%/PD
42.93
27.77
41.28
27.59
37.90
29.96
tb
872
792.76
6.6
4.9
0.06
6.5
5.6
0.26
0.18
%/PD
94.44
67
92.02
94.25
97.16
92.48
psy
417
354
3.1
2.3
0.1
3.3
2.9
0.4
0.04
%/PD
47.48
42.83
45.97
44.46
47.31
37.35
soc
611
521
4.9
3.7
0.08
5.2
3.6
0.03
0.012
%/PD
63.31
63.31
64.93
63.93
78.08
53.97

Numbers in column fw/ sw, 2019/ 2020 represent the mean numbers of cases per mo (1-3) or per mo and site (4-9).

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Other Colorectal and Anal Cancer

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 3626)

DOI

10.1200/JCO.2022.40.16_suppl.3626

Abstract #

3626

Poster Bd #

419

Abstract Disclosures

Similar Abstracts

First Author: Joshua Ling

First Author: Ahmed Abdelhakeem

Abstract

2024 ASCO Annual Meeting

Cost effectiveness of colorectal cancer screening in the Dominican Republic.

First Author: Yoanna S. Pumpalova